You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GLP-1 receptor agonist; exenatide

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetes, Type 2 Trial in San Antonio (Placebo, Exenatide, Dapagliflozin)

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Placebo
  • +3 more
  • San Antonio, Texas
    University Health System Texas Diabetic Institute
Apr 28, 2022

Ischemic Stroke Trial in Herlev (Byetta, Normosaline)

Recruiting
  • Ischemic Stroke
  • Herlev, Denmark
    Department of Neurology, Herlev-Gentofte Hospital
Nov 13, 2021

Type 2 Diabetes, Obesity Trial in Amsterdam (Dapagliflozin 10mg, Exenatide, exenatide)

Completed
  • Type 2 Diabetes Mellitus
  • Obesity
  • Dapagliflozin 10mg
  • +3 more
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC, location VU Medical Center
Jun 8, 2021

Type 2 Diabetes Trial in Lancaster (Exenatide Injection, Saline injection)

Terminated
  • Type 2 Diabetes
  • Exenatide Injection
  • Saline injection
  • Lancaster, Pennsylvania
    Amish Research Clinic
Mar 6, 2023

Alcohol Dependence, in Remission, Addiction, Alcohol Trial in Copenhagen (Exenatide 2 MG Injection, BD PosiFlush (saline))

Completed
  • Alcohol Dependence, in Remission
  • Addiction, Alcohol
  • Exenatide 2 MG Injection
  • BD PosiFlush (saline)
  • Copenhagen, Frederiksberg, Denmark
    Novavì ambulatorierne
Jun 3, 2021

Incidence of Retained Gastric Food on Endoscopy

Not yet recruiting
  • Gastric Content Aspiration
  • Esophagogastroduodenoscopy
  • (no location specified)
May 16, 2023

Caveolin 1 Deficiency in Response to Glucagon-like Peptide 1

Not yet recruiting
  • Overweight and Obesity
  • 24-hour ambulatory blood pressure
  • Liberal salt diet
  • (no location specified)
Oct 4, 2023

Type 2 Diabetes Trial in Xuzhou (GLP-1 receptor agonist)

Recruiting
  • Type 2 Diabetes Mellitus
  • GLP-1 receptor agonist
  • Xuzhou, Jiangsu, China
    Department of Endocrinology
Apr 16, 2022

Glucagon-like Peptide-1 Receptor Agonists According to Type 2

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Bari, Italy
    Azienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023

Cocaine Use Disorder Trial in Houston (Exenatide 2 mg [Bydureon], Drug Counseling)

Completed
Has Results
  • Cocaine Use Disorder
  • Exenatide 2 mg [Bydureon]
  • Drug Counseling
  • Houston, Texas
    UTHealth Behavioral and Biomedical Sciences Building
May 31, 2022

A Pan-European Post-Authorisation Safety Study: Risk of

Not yet recruiting
  • Pancreatic Cancer
  • Exenatide
  • Non-GLP-1 RA based glucose lowering drugs
  • (no location specified)
Dec 21, 2022

Alcohol Use Disorder Trial in Boston (Exenatide, Sham injection)

Terminated
Has Results
  • Alcohol Use Disorder
  • Boston, Massachusetts
    Boston University Psychiatry Research Center, Clinical Studies U
Jan 14, 2022

Morbid Obesity, Metabolic Syndrome, Diabetes Trial in Columbia (GLP-1 receptor agonist)

Not yet recruiting
  • Morbid Obesity
  • +4 more
  • GLP-1 receptor agonist
  • Columbia, Missouri
    University of Missouri Hospital
Nov 20, 2023

Osteoporosis, Postmenopausal, Diabetes, Type 2 Trial in Jackson (GLP-1 receptor agonist)

Recruiting
  • Osteoporosis, Postmenopausal
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Jackson, Mississippi
    University of Mississippi Medical Center
Aug 5, 2022

Glucagon-like Peptide 1 Receptor Agonists and Mental Health

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • GLP-1 receptor agonist
  • (no location specified)
Aug 4, 2022

Healthy Trial in Singapore (LY3537021, Liraglutide, Placebo)

Active, not recruiting
  • Healthy
  • Singapore, Singapore
    Lilly Centre for Clinical Pharmacology
Nov 22, 2022

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS ,

Active, not recruiting
  • Weight Loss
  • +3 more
  • GLP-1 receptor agonist
  • Culleredo, A Coruña, Spain
  • +10 more
Jan 13, 2023

Parkinson's Disease Trial in Gainesville (Exenatide)

Completed
  • Parkinson's Disease
  • Gainesville, Florida
    Laboratory for Rehabilitation Neuroscience
Sep 14, 2022

Alcohol Abuse, Alcohol Addiction, Alcohol Dependence Trial in Frederiksberg (Semaglutide Injectable Product, Placebo)

Recruiting
  • Alcohol Abuse
  • +3 more
  • Semaglutide Injectable Product
  • Placebo
  • Frederiksberg, Denmark
    Psychiatric Center Copenhagen, Frederiksberg Hospital
Jun 13, 2023

Semaglutide Use in Acute Pulmonary Embolism

Completed
  • Pulmonary Embolism
  • London, United Kingdom
    Colm McCabe
Nov 3, 2023

Obesity Trial in Ras al-Khaimah (POSE2.0 Endoscopic Gastric Remodeling, Liraglutide injection)

Recruiting
  • Obesity
  • POSE2.0 Endoscopic Gastric Remodeling
  • Liraglutide injection
  • Ras al-Khaimah, United Arab Emirates
    Ibrahim Bin Hamad Obaidullah Hospital
Jan 27, 2023

Diabetes Trial in Nanjing (Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc)

Recruiting
  • Diabetes
  • Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Aug 6, 2023

Cerebral Small Vessel Disease Trial in Hong Kong (Exenatide extended release)

Recruiting
  • Cerebral Small Vessel Disease
  • Exenatide extended release
  • Hong Kong, Hong Kong
    Chinese University of Hong Kong
Jul 18, 2022

Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)

Not yet recruiting
  • Obesity
  • +16 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 14, 2023

Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance Trial in Philadelphia (Dulaglutide 0.75Mg/0.5Ml Inj Pen)

Recruiting
  • Cystic Fibrosis
  • +3 more
  • Dulaglutide 0.75Mg/0.5Ml Inj Pen
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 11, 2023